Table 3 Increase in the relative frequency (%) of different outcomes and the number needed to treat (NNT) with respective 95% CIs calculated using a normal approximation compared to the placebo. - Data were not reported in the studies. Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

Infliximab [111]

–

–

42

2.4 (1.9–3.2)

–

–

35

2.9 (2.2–4.0)

–

–

21

4.7 (3.7–6.7)

Etanercept [113, 119, 120, 123]

27

3.7 (2.9–5.1)

34

2.9 (2.2–4.3)

18

5.5 (3.6–11.7)

–

–

13

7.5 (3.7-∞)

13

7.6 (4.9–16.9)

Adalimumab [126, 130, 131]

27

3.7 (2.8–5.2)

–

–

26

3.8 (3.0–5.2)

26

3.8 (2.8–5.8)

16

6.4 (4.8–9.5)

17

6.1 (4.2–10.7)

Golimumab [133, 137, 138]

37

2.7 (2.3–3.4)

–

–

40

2.5 (2.1–3.2)

28

3.6 (2.5–6.0)

–

7.5 (4.8–16.3)

–

–

Certolizumab pegol [139]

22

4.5 (3.0–9.1)

–

–

28

3.6 (2.6–5.5)

–

–

20

5.0 (3.7–7.5)

–

–

Secukinumab [142]

36

2.8 (2.2–3.8)

–

–

30

3.3 (2.5–4.6)

–

–

12

8.1 (5.4–16.0)

–

–